KIT and gastrointestinal stromal tumor: In the subset of patients with KIT exon 11 deletion/indel mutation, which are the most common mutations in GIST and considered imatinib-sensitive [18], 3-year adjuvant imatinib led to 66% reduction in the risk of death compared to 1 year of adjuvant imatinib [17].